Phase 1 Mirdametinib Trial for CNS Tumors

NIH added a new Phase 1 clinical trial registration for mirdametinib (a targeted therapy) in patients with central nervous system tumors. The trial covers two conditions: glioma and neurohistiocytosis. No regulatory obligations arise from this registration notice itself.\n\nFor pharmaceutical sponsors and clinical investigators, this registration demonstrates continued NIH oversight of oncology trial activity. Trial sponsors conducting applicable clinical trials should ensure compliance with ClinicalTrials.gov registration and results reporting requirements under FDAAA 801.